Ma CX - Search Results

1

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.

Dowsett M, Ellis MJ, Dixon JM, Gluz O, Robertson J, Kates R, Suman VJ, Turnbull AK, Nitz U, Christgen M, Kreipe H, Kuemmel S, Bliss JM, Barry P, Johnston SR, Jacobs SA, Ma CX, Smith IE, Harbeck N. Dowsett M, et al. Among authors: ma cx. NPJ Breast Cancer. 2020 Jun 8;6:21. doi: 10.1038/s41523-020-0168-9. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32550266 Free PMC article.

2

Neoadjuvant endocrine therapy for locally advanced breast cancer.

Ma CX, Ellis MJ. Ma CX, et al. Semin Oncol. 2006 Dec;33(6):650-6. doi: 10.1053/j.seminoncol.2006.08.013. Semin Oncol. 2006. PMID: 17145344 Review.

3

Letrozole in the neoadjuvant setting: the P024 trial.

Ellis MJ, Ma C. Ellis MJ, et al. Breast Cancer Res Treat. 2007;105 Suppl 1(Suppl 1):33-43. doi: 10.1007/s10549-007-9701-x. Epub 2007 Oct 3. Breast Cancer Res Treat. 2007. PMID: 17912634 Free PMC article. Clinical Trial.

4

Femara and the future: tailoring treatment and combination therapies with Femara.

Ellis M, Ma C. Ellis M, et al. Breast Cancer Res Treat. 2007;105 Suppl 1(Suppl 1):105-15. doi: 10.1007/s10549-007-9697-2. Epub 2007 Oct 3. Breast Cancer Res Treat. 2007. PMID: 17912640 Free PMC article. Review.

5

Predicting endocrine therapy responsiveness in breast cancer.

Ma CX, Sanchez CG, Ellis MJ. Ma CX, et al. Oncology (Williston Park). 2009 Feb;23(2):133-42. Oncology (Williston Park). 2009. PMID: 19323294 Free article. Review.

6

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.

Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C. Croghan GA, et al. Cancer. 2010 Jul 15;116(14):3463-8. doi: 10.1002/cncr.25191. Cancer. 2010. PMID: 20564112 Free PMC article. Clinical Trial.

7

Neoadjuvant endocrine therapy for breast cancer.

Chawla JS, Ma CX, Ellis MJ. Chawla JS, et al. Among authors: ma cx. Surg Oncol Clin N Am. 2010 Jul;19(3):627-38. doi: 10.1016/j.soc.2010.04.004. Surg Oncol Clin N Am. 2010. PMID: 20620931 Review.

8

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Chia YH, Ellis MJ, Ma CX. Chia YH, et al. Among authors: ma cx. Br J Cancer. 2010 Sep 7;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10. Br J Cancer. 2010. PMID: 20700118 Free PMC article. Review.

9

High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.

Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R. Napoli N, et al. Breast J. 2010 Nov-Dec;16(6):609-16. doi: 10.1111/j.1524-4741.2010.01012.x. Breast J. 2010. PMID: 21070438 Free PMC article.

10

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ. Sanchez CG, et al. Among authors: ma cx. Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833. Breast Cancer Res. 2011. PMID: 21362200 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page